园林绿化工程

Search documents
金埔园林股价微涨0.62%,临时股东大会明日召开
Jin Rong Jie· 2025-08-18 17:01
截至2025年8月18日收盘,金埔园林股价报9.71元,较前一交易日上涨0.62%,成交额0.61亿元,换手率 4.22%。 资金流向方面,8月18日主力资金净流入242.92万元,占流通市值0.17%,近五日主力资金净流出81.84 万元。 风险提示:市场有风险,投资需谨慎。 金埔园林属于工程建设板块,主营业务涵盖园林绿化工程设计、施工及养护等。公司总部位于江苏南 京,市值规模较小,流通市值14.53亿元。 消息面上,金埔园林将于8月19日召开2025年第二次临时股东大会,审议调整募集资金内部投资结构及 新增募投项目的议案。 ...
破发股园林股份上半年增亏 2021上市募6.6亿已连亏3年
Zhong Guo Jing Ji Wang· 2025-07-11 03:38
Core Viewpoint - Garden Co. (园林股份) is expected to report a significant net loss for the first half of 2025, with estimates ranging from -92 million to -68 million yuan, primarily due to reduced construction volume and slow payment collection [1] Financial Performance - The company reported a total profit of -66.56 million yuan for the same period last year, with a net profit of -60.42 million yuan [1] - The net profit excluding non-recurring gains and losses for the previous year was -68.72 million yuan [1] - In 2024, the company achieved an operating income of 722 million yuan, a year-on-year increase of 14.91%, but still reported a net loss of -190 million yuan [3] - The net profit excluding non-recurring gains and losses for 2024 was -200 million yuan, compared to -159 million yuan the previous year [3] - In 2022, the company had an operating income of 514 million yuan and a net profit of -262 million yuan [3] Company Background - Garden Co. was listed on the Shanghai Stock Exchange on March 1, 2021, with an initial issuance of 40.31 million shares at a price of 16.38 yuan per share [2] - The total funds raised from the IPO amounted to 660 million yuan, with a net amount of 585 million yuan after deducting issuance costs [2] - The company has been operating at a loss for three consecutive years [3]
四环生物高层换血背后:原实控人涉内幕交易被判刑,四年亏损近2.7亿元触发退市危机,“碧水系”入主能否力挽狂澜
Hua Xia Shi Bao· 2025-06-05 03:53
Core Viewpoint - Sihuan Bio is facing a critical survival challenge due to poor performance and a risk of delisting, following significant management changes and a new controlling shareholder [2][8]. Group 1: Management Changes - Sihuan Bio's board received resignation letters from key executives, including the chairman and independent directors, leading to a complete management overhaul [2]. - Chen Long has been appointed as the new general manager, with Liu Xiaofeng, Wei Linfu, and Zhou Yang taking on vice president roles [2]. Group 2: Financial Performance - In 2024, Sihuan Bio reported revenue of 204 million yuan, a year-on-year decline of 13.55%, and has faced cumulative losses of nearly 270 million yuan over four years [2][10]. - The company has triggered delisting warnings due to negative net profits and revenues below 300 million yuan [2][14]. - The pharmaceutical segment generated 198 million yuan, accounting for 97.34% of total revenue, but also saw a decline of 12.33% [9]. Group 3: Shareholder Changes - The former controlling shareholder, Lu Keping, was sentenced for insider trading, leading to the judicial auction of his 27.78% stake, which was acquired by Fujian Bihui Agricultural Investment Co., Ltd. for 388 million yuan [6][10]. - The new controlling shareholder, Qiu Weibin, has not yet disclosed specific plans for resource injection or strategic direction for Sihuan Bio [7]. Group 4: Industry Challenges - Sihuan Bio is grappling with a dual crisis of "industry decline and governance failure," with its pharmaceutical products facing intense competition and price controls due to healthcare policies [8][10]. - The company has seen a consistent decline in revenue and net profit from 2021 to 2023, with losses increasing significantly in 2024 [9][10]. Group 5: Future Outlook - Sihuan Bio must achieve over 300 million yuan in revenue and positive net profit by 2025 to avoid delisting, presenting a significant challenge for the new management team [2][14]. - The company has increased R&D spending to 9.05 million yuan in Q1 2025, indicating a commitment to innovation despite ongoing financial pressures [10][11].